Manganese sulfate monohydrate
10034-96-5O.O=S(=O)([O-])[O-].[Mn+2]ISPYRSDWRDQNSW-UHFFFAOYSA-LManganese(ii) sulfate monohydrate appears as odorless pale red slightly efflorescent crystals or light pink powder. pH (5% solution) 3.7. (NTP, 1992)
2.95 (NTP, 1992) - Denser than water; will sink
Relative density (water = 1): 2.95
3.25 @25 °C
50 to 100 mg/mL at 70 °F (NTP, 1992)
Solubility in water, g/100ml: 76.2 (freely soluble)
greater than 752 °F (NTP, 1992)
400-450 °C
700 °C
Manganese(ii) sulfate monohydrate appears as odorless pale red slightly efflorescent crystals or light pink powder. pH (5% solution) 3.7. (NTP, 1992)
Dry Powder; Other Solid; Dry Powder; Liquid; Liquid
Light red solid; Slightly efflorescent; [Merck Index] Pink hygroscopic solid; [ICSC] Light red hygroscopic powder; [Aldrich MSDS]
PINK HYGROSCOPIC CRYSTALS.
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
This chemical does not meet GHS hazard criteria for 0.1% (2 of 1512) of reports.
Warning
H373 (99.7%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]
P260, P273, P319, P391, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 1512 reports by companies from 23 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Warning
Chemical: Sulfuric acid, manganese(2+) salt (1:1), monohydrate
Regulation (EC) No 1831/2003 (amended)
Sulfuric acid, manganese(2+) salt (1:1) monohydrate is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Sulfuric acid, manganese(2+) salt (1:1) monohydrate are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)
Manganese (II) sulphate, monohydrate: Does not have an individual approval but may be used under an appropriate group standard
Flash point data for this chemical are not available; however, it is probably combustible. (NTP, 1992)
Not combustible. Gives off irritating or toxic fumes (or gases) in a fire.
SYMPTOMS: Symptoms of exposure to this compound include mild irritation of the eyes and mucous membranes of the respiratory tract. Symptoms of exposure to this type of compound include apathy, anorexia, headache, recurring leg cramps, loss of balance, clumsiness, pneumonia and associated pulmonary problems. Other symptoms include central nervous system damage, pulmonary system damage, upper respiratory infections, languor, sleepiness, weakness in the legs, a stolid, mask-like face, muscular twitchings, varying from a fine tremor of the hands to coarse, rhythmical movements of the arms, legs and trunk; slight increase in tendon reflexes, ankle and patellar clonus, typical Parkinsonian slapping gait and minute handwriting (affected by micrographia). It can cause spastic gait, insomnia, dystonia, fatiguability, asthenia and an inability to concentrate. It can also cause impaired mentation, ataxia, difficulty in walking and decreased movement of the eyelids and eyes. Other symptoms include lethargy, edema, extrapyramidal effects, sleep disturbances, dermatitis, irritability, liver enlargement, increased muscle tone, muscular cramps, mental deterioration, excessive salivation and perspiration, sexual disturbances, blood changes and, very rarely, hypothyroidism. Exposure can cause spasms, arthralgias and speech disturbances such as slurred speech, slow and monotonous voice tone, inability to speak above a whisper, difficult articulation and incoherence, and even complete muteness. Psychosis may occur with unaccountable laughter, euphoria, impulsive acts, absentmindedness, mental confusion, aggressiveness and hallucinations. Propulsion, retropropulsion and lateropropulsion are affected with no movement for protection when falling. Absolute detachment may occur, broken by sporadic or spasmodic laughter. Inhalation may cause acute bronchitis, nasopharyngitis and itching. Numbness of the extremities and impairment of libido may occur. Other effects include weakness, delusions, compulsions, rigidity, bradykinesia, sudden crying, stuttering, hoarse voice, nervousness, inability to walk backward, hyporeflexia, Romberg's sign, adiadochokinesia, forgetfulness, general malaise, drowsiness, stiffness of the arms or legs, urinary difficulty, somnolence, sexual excitement followed by impotence, "hen's gait" and frequent falling. Fever may occur, with chills, upset stomach (nausea), vomiting, dryness of the throat, cough and body aches. Other symptoms include trouble with memory and judgment, unstable emotions, incoordination, chest pain, restlessness, double vision, impaired hearing, anemia, lassitude and low back pain. Symptoms of exposure may simulate progressive bulbar paralysis, post-encephalitic Parkinsonism, multiple sclerosis, amyotrophic lateral sclerosis and progressive lenticular degeneration (Wilson's Disease).
Used in dyes, boiling oils for varnishes, fertilizers (vines and tobacco), animal feeds (essential trace element), red glazes on porcelain, and medicines (prevention of perosis in poultry); [Merck Index] Used in paints, varnishes, textile dyes, fungicides, medications, ceramics, foods (nutrient and dietary supplement), ore flotation, and synthetic manganese dioxide; Also used as a catalyst (viscose process); [NTP]
Painting (Pigments, Binders, and Biocides) [Category: Paint]
Ceramics making [Category: Hobbies]
用途乾燥剤、窯業用顔料、金属防錆、肥料、マンガン塩製造、触媒
使用Manganese sulfate monohydrate is used to produce manganese by an electrolytic process. The compound is used for dyeing textiles; for producing red glazes on porcelain; in varnish driers; in fertilizers; and in animal feeds to provide manganese as an essential trace element.
一般的な説明Odorless pale red slightly efflorescent crystals or light pink powder. pH (5% solution) 3.7.
製造方法Manganese(II) sulfate is prepared by prolonged heating of any manganese salt with concentrated sulfuric acid. The compound is produced commercially from pyrolusite (MnO2) or rhodochrosite (MnCO3). Either mineral is dissolved in sulfuric acid and the solution evaporated: MnO2 + H2SO4 → MnSO4 + H2O + ½ O2 Alternatively, manganese dioxide is heated strongly with dehydrated iron(II) sulfate: 2MnO2 + 2FeSO4 → 2MnSO4 + Fe2O3 + ½ O2 Manganese(II) sulfate, prepared by methods involving evaporation of manganese salt with sulfuric acid, is the tetrahydrate, MnSO4•4H2O. The tetrahydrate on gentle heating produces monohydrate, MnSO4•H2O. Also, manganese(II) sulfate is a by-product in the manufacture of hydroquinone. The process involves reaction of aniline with manganese dioxide in sulfuric acid, followed by the removal of quinone by steam distillation under vacuum. 2C6H5NH2 (aniline) + 5H2SO4 + 4MnO2 → 2C6H4O2 + 4MnSO4 + 2C6H4O2 + 4MnSO4(quinone) The unreacted acid is neutralized by lime, treated with water, and the solution filtered to separate any excess MnO2 and insoluble residues. Evaporation of the filtrate yields a crude product containing about 80% MnSO4 and 15% (NH4)2SO4. Manganese(II) sulfate also may be produced by the action of sulfur dioxide with manganese dioxide: MnO2 + SO2 → MnSO4
10034-96-5、15244-36-7DTXSID4020795CHEBI:86364化学的特性Pale pink crystalline powder, slightly hygroscopic
No evidence of carcinogenicity in rats and equivocal evidence in mice in 2-year feeding studies; [NTP] Intermittent inhalation studies of rats produced changes in testicular weight (0.5 mg/m3 for 45 days) and degenerative changes to brain (0.01 mg/m3 for 13 weeks); [RTECS] May cause irritation; Targets lungs and nerves; [Aldrich MSDS] See Manganese and linked occupational diseases.
STOT RE 2 (99.7%)
STOT RE 2 (100%)
Acute toxicity - category 4
Germ cell mutagenicity - Category 2
Acute toxicity (Oral) - Category 4
Fires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. A water spray may also be used. (NTP, 1992)
In case of fire in the surroundings, use appropriate extinguishing media.
Fresh air, rest.
Rinse with plenty of water for several minutes (remove contact lenses if easily possible).
Rinse mouth. Seek medical attention if you feel unwell.
EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.
SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.
Personal protection: particulate filter respirator adapted to the airborne concentration of the substance. Do NOT let this chemical enter the environment. Sweep spilled substance into covered containers. If appropriate, moisten first to prevent dusting. Wash away remainder with plenty of water. Store and dispose of according to local regulations.
Cough. Sore throat. Shortness of breath.
Redness. Pain.
Sore throat.
Manganese Sulfate Monohydrate
TR-428: Toxicology and Carcinogenesis Studies of Manganese (II) Sulfate Monohydrate (CASRN 10034-96-5) in F344/N Rats and B6C3F1 Mice (Feed Studies) (1993 )
06/23/92
No Evidence
No Evidence
Equivocal Evidence
純化方法Crystallise it from water (0.9mL/g) at 54-55o by evaporating about two-thirds of the water. It dehydrates above 400o.
定義本品は、硫酸(*)のマンガン塩であり、次の化学式で表される。参照表示名称:硫酸